Episode: Dr. Sean J. Pittock Discusses Autoimmune Epilepsy

Neurology Today - Neurology Today Podcast Logo
Dr. Sean J. Pittock Discusses Autoimmune Epilepsy
Sean J. Pittock, MD, an associate professor of neurology and co-director of the Neuroimmunology Laboratory at Mayo Clinic, and colleagues published an April 4 Neurology study on autoimmune epilepsy. The Mayo researchers found encouraging, but preliminary results for the use of immunotherapy in medically intractable patients with suspected autoimmune epilepsy. In this interview, Dr. Pittock discusses the findings, and what future studies are necessary. See the associated article in the May 1 issue of Neurology Today.

Neurology Today - Neurology Today Podcast
Users who viewed this episode also viewed...

Neurology Today - Neurology Today Podcast > New Data: Could Olfactory Deficits Be Risk Factors for Dementia?

Two new studies presented at the Alzheimer’s Association meeting in Copenhagen found that people in the early stages of Alzheimer’s have subtle deficits in odor identification, a finding that could help diagnose the disease very early on. In this podcast, Neurology Today speaks with Mark Albers, MD, PhD, assistant professor of neurology at Harvard University and a neurologist at Massachusetts General Hospital, and Davangere Devanand, MD, professor of psychiatry at Columbia University Medical Center, about their research...

Neurology Today - Neurology Today Podcast > Brain Death in the News Again — Neuroethicist James L. Bernat, MD, Responds

The concept of death by neurologic criteria — the irreversible loss of the clinical function of the whole brain, commonly known as brain death — was at the center of a very public ethical debate after two tragic stories-turned-legal-battles took the media by storm in January. In this podcast interview, James L...

Neurology Today - Neurology Today Podcast > LISTEN UP: DUCHENNE MUSCULAR DYSTROPHY: What happened to 20-year-old comparative data on two corticosteroids for Duchenne muscular dystrophy (DMD) — and what does it mean for the DMD therapy pipeline now?

The Food and Drug Administration is considering a new drug application for deflazacort based on data from a 1995 study released in Neurology. Here, the senior study author Robert C. Griggs, MD, FAAN, professor of neurology, medicine, pediatrics, pathology & laboratory medicine in the Center for Human Experimental Therapeutics at the University of Rochester School of Medicine and Dentistry, discusses what the findings could mean for DMD therapy...
Comments (0)

Login or Sign up to leave a comment.

Log in
Sign up

Be the first to comment.